Indoxyl Sulfate, a Uremic Endotheliotoxin - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Access content directly
Journal Articles Toxins Year : 2020

Indoxyl Sulfate, a Uremic Endotheliotoxin


Chronic kidney disease (CKD) is associated with a high prevalence of cardiovascular diseases. During CKD, the uremic toxin indoxyl sulfate (IS)-derived from tryptophan metabolism-accumulates. IS is involved in the pathophysiology of cardiovascular complications. IS can be described as an endotheliotoxin: IS induces endothelial dysfunction implicated in cardiovascular morbidity and mortality during CKD. In this review, we describe clinical and experimental evidence for IS endothelial toxicity and focus on the various molecular pathways implicated. In patients with CKD, plasma concentrations of IS correlate with cardiovascular events and mortality, with vascular calcification and atherosclerotic markers. Moreover, IS induces a prothrombotic state and impaired neovascularization. IS reduction by AST-120 reverse these abnormalities. In vitro, IS induces endothelial aryl hydrocarbon receptor (AhR) activation and proinflammatory transcription factors as NF-kappa B or AP-1. IS has a prooxidant effect with reduction of nitric oxide (NO) bioavailability. Finally, IS alters endothelial cell and endothelial progenitor cell migration, regeneration and control vascular smooth muscle cells proliferation. Reducing IS endothelial toxicity appears to be necessary to improve cardiovascular health in CKD patients.
Fichier principal
Vignette du fichier
toxins-12-00229.pdf (1.53 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03158887 , version 1 (07-07-2023)



Guillaume Lano, Stéphane Burtey, Marion Sallee. Indoxyl Sulfate, a Uremic Endotheliotoxin. Toxins, 2020, 12 (4), pp.229. ⟨10.3390/toxins12040229⟩. ⟨hal-03158887⟩
38 View
0 Download



Gmail Facebook Twitter LinkedIn More